CTLA-4, LAG-3, TIGIT & Other Checkpoints

Cat. No.

AT0873

CAS No.

2229859-11-2

Mirzotamab

Mirzotamab is an IgG1κ monoclonal antibody specifically designed to target CD276 (also known as B7-H3), a protein frequently overexpressed in various tumor cells. This antibody exhibits potent anti-tumor properties. In its conjugated form, mirzotamab is linked to Clezutoclax, a BCL-2 family inhibitor, creating the antibody-drug conjugate (ADC) known as Mirzotamab Clezutoclax (ABBV-155). This ADC is currently under investigation for its efficacy in combination with taxane therapy in the treatment of relapsed or refractory solid tumors, highlighting its potential as a therapeutic in oncological research.

Cat. No.

AT0896

CAS No.

2768355-20-8

Lancastotug

Lancastotug is a human IgG1 κ monoclonal antibody targeting TIGIT. For optimal experimental control, the use of Human IgG1 kappa Isotype Control is recommended.

Cat. No.

AT0909

CAS No.

2850355-80-3

Tazlestobart

Tazlestobart is a humanized IgG1κ monoclonal antibody designed to specifically target CTLA4. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT0918

CAS No.

2231305-30-7

Vibostolimab

Vibostolimab is a monoclonal antibody targeting TIGIT (T cell immunoglobulin and ITIM domain), demonstrating significant antitumor activity. This antibody is specifically designed for research involving non-small cell lung cancer (NSCLC) and melanoma, providing a valuable tool for investigations into immune checkpoint pathways and cancer immunotherapy.

Cat. No.

AT0939

CAS No.

1918185-84-8

Tiragolumab

Synonyms: MTIG-7192A; RG-6058

Tiragolumab functions as an immune checkpoint inhibitor by targeting the T-cell immunoglobulin and ITIM domain (TIGIT). This monoclonal antibody can be utilized either as a monotherapy or in conjunction with Atezolizumab, a PD-L1 inhibitor, to potentially enhance therapeutic efficacy against a variety of solid tumors, with a notable application in the treatment of non-small cell lung cancer (NSCLC). This dual approach may offer a strategic advantage in the modulation of immune responses in oncology settings.

Cat. No.

AT0942

CAS No.

2635407-50-8

Venanprubart

Venanprubart is a human IgG4 κ monoclonal antibody targeting BTLA (B and T Lymphocyte Attenuator). For optimal experimental control, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This antibody is designed for the specific detection and study of BTLA's role in immune regulation, making it an essential tool for immunology research.

Cat. No.

AT0956

CAS No.

2460399-39-5

Evalstotug

Evalstotug is a human IgG1 κ monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4). For accurate experimental control, it is recommended to use Human IgG1 kappa isotype control.

Cat. No.

AT0969

Anti-B7-H3/CD276 Antibody

The Anti-B7-H3/CD276 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells specifically targeting the B7-H3/CD276 antigen. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, and exhibits a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa Isotype Control is recommended as a suitable reference standard. This antibody is essential for studies focusing on the role of the B7-H3/CD276 pathway in immune regulation and cancer immunotherapy.

Cat. No.

AT1014

CAS No.

2725062-35-9

Renvistobart

Renvistobart is a monoclonal antibody of the immunoglobulin G1-κ class, specifically targeting the T cell immunoreceptor with Ig and ITIM domains (TIGIT), also known as VSIG9 or VSTM3, in Homo sapiens. This antibody binds selectively to the TIGIT receptor, which plays a critical role in the regulation of T cell function and immune response, making it a valuable tool for research in immunology and therapeutic development.

Cat. No.

AT1031

CAS No.

3006784-09-1

Trovostobart

Trovostobart is a monoclonal antibody of the human IgG1 κ isotype, specifically targeting V-set immunoregulatory receptor (VSIR). For experimental controls, it is recommended to use Human IgG1 kappa Isotype Control.

Cat. No.

AT1037

CAS No.

2126132-98-5

Fianlimab

Synonyms: REGN3767

Fianlimab (REGN3767) is a human monoclonal antibody designed to specifically bind to the lymphocyte-activation gene 3 (LAG-3) immune checkpoint receptor expressed on T cells. This interaction inhibits the LAG-3 pathway, thereby enhancing T cell function and exhibiting potent anti-tumor activity. Fianlimab is utilized in oncological research to investigate immune checkpoint blockade as a strategy for cancer immunotherapy.

Cat. No.

AT1053

CAS No.

2245966-28-1

Daxdilimab

Synonyms: MEDI7734; VIB7734

Daxdilimab is a monoclonal antibody that targets ILT7, a cell surface molecule uniquely expressed on plasmacytoid dendritic cells (pDCs). This antibody has been specifically developed for research purposes, particularly to investigate its therapeutic potential in managing acute lung injury (ALI) associated with COVID-19 infection. Daxdilimab offers a promising tool for elucidating the role of pDCs in viral infections and inflammatory responses.

Cat. No.

AT1055

NTX-1088

Ntx1088 is a first-in-class, potent monoclonal antibody that targets the poliovirus receptor, also known as CD155. This antibody has demonstrated potential therapeutic applications in the treatment of patients with locally advanced and metastatic solid tumors. Its specific interaction with CD155 makes it a valuable tool for research and potential clinical use in oncology.

Cat. No.

AT1096

CAS No.

2649466-03-3

Tuparstobart

Synonyms: Incagn-02385

Tuparstobart (Incagn-02385) is an IgG1κ monoclonal antibody designed to specifically target LAG-3, an immune checkpoint receptor. LAG-3 is predominantly expressed on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells. This antibody is engineered to bind to LAG-3, thereby modulating immune responses, which may be critical in the research of immune regulation and potential therapeutic applications in immune-related disorders.

Cat. No.

AT1097

CAS No.

2645437-82-5

Nelistotug

Nelistotug (GSK 6097608; GSK6097608) is a human IgG1κ monoclonal antibody that specifically targets CD96. This antibody is designed for the precise identification and study of CD96 expression in various biological research applications. It is particularly useful in investigating the role of CD96 in immune response modulation and its potential implications in immunotherapy.

Cat. No.

AT1107

CAS No.

1673516-98-7

Relatlimab

Synonyms: BMS-986016

Relatlimab (BMS-986016) is a human monoclonal antibody targeting LAG-3, developed through the immunization of transgenic mice engineered to express human immunoglobulin miniloci, using recombinant LAG-3 protein. This antibody effectively inhibits the interaction between LAG-3 and MHC II with an IC50 of 0.67 nM, and between LAG-3 and FGL1 with an IC50 of 0.019 nM. It is primarily utilized in cancer research, providing a valuable tool for investigating the role of LAG-3 in tumor immune evasion and potential therapeutic interventions.

Cat. No.

AT1123

CAS No.

2762201-85-2

Uprevstobart

Uprevstobart is a human IgG1 κ monoclonal antibody targeting NT5E. For experimental control purposes, it is recommended to use Human IgG1 kappa Isotype Control.

Cat. No.

AT1159

CAS No.

2904575-77-3

Zadoprubart

Zadoprubart is a humanized IgG4κ monoclonal antibody specifically targeting BTLA (B and T Lymphocyte Attenuator). For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity and control recommendation ensure precise targeting and accurate data interpretation in research applications focusing on immune modulation.

Cat. No.

AT1169

Anti-B7-H4/VTCN1 Antibody

The Anti-B7-H4/VTCN1 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the B7-H4/VTCN1 antigen, a protein implicated in the regulation of immune response. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and it has a predicted molecular weight of 145 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa. This product is ideal for use in research applications focusing on immune modulation and cancer immunotherapy.

Cat. No.

AT1179

CAS No.

2249882-55-9

Miptenalimab

Synonyms: BI-754111

Miptenalimab (BI-754111) is a monoclonal antibody targeting human LAG-3 with a dissociation constant (K_D) of 88.6 nM. This antibody effectively inhibits the interaction between LAG-3 and its physiological ligand MHC class II, highlighting its potential utility in modulating immune responses in oncological and immunological research.

Cat. No.

AT1239

CAS No.

477202-00-9

Ipilimumab

Synonyms: MDX-010; BMS-734016

Ipilimumab is a fully human monoclonal antibody of the IgG1κ isotype designed to inhibit the cytotoxic T lymphocyte antigen 4 (CTLA-4) receptor on T cells. This antibody is utilized in research focused on unresectable or metastatic melanoma (MM), serving as a critical tool in investigating the modulation of immune checkpoints in cancer therapy.

Cat. No.

AT1248

Anti-LILRB4/ILT3/CD85k Antibody

The Anti-LILRB4/ILT3/CD85k Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the LILRB4/ILT3/CD85k antigen, a critical regulatory receptor expressed on the surface of immune cells. With a molecular weight of approximately 144.36 kDa, this antibody serves as a valuable tool for the study of immune checkpoint regulation and potential therapeutic intervention in immune-related disorders.

Cat. No.

AT1256

CAS No.

2368219-35-4

Domvanalimab

Synonyms: AB154

Domvanalimab (AB154) is a humanized monoclonal antibody targeting TIGIT (T cell immunoreceptor with Ig and ITIM domains). This antibody selectively binds to human TIGIT, effectively inhibiting the interaction between TIGIT and its ligand CD155. Domvanalimab is primarily utilized in oncological research to explore the modulation of immune responses against cancer cells. This inhibition potentially enhances T cell activation and NK cell cytotoxicity, offering a promising avenue for cancer immunotherapy studies.

Cat. No.

AT1264

CAS No.

2550560-20-6

Dresbuxelimab

Synonyms: AK-119

Dresbuxelimab (AK-119) is an IgG-κ monoclonal antibody specifically designed to target CD73. It is produced using a Chinese Hamster Ovary (CHO) cell expression system. This antibody has potential applications in research focused on the enzymatic activity of CD73 and its role in immunosuppressive pathways, making it a valuable tool for studies in immunology and cancer research.

Cat. No.

AT1283

CAS No.

2360418-68-2

Negalstobart

Negalstobart is a human IgG4 κ monoclonal antibody targeting LAG-3. For control experiments, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.